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ABSTRACT 
BACKGROUND:  Clozapine has been associated with metabolic adverse vents (AEs) 
(eg, elevated body weight, blood glucose concentrations, cholesterol, triglycerides [TG]), 
all of which have deleterious effbcts on health and medication compliance. However, 
little fbcus has been directed toward finding a suitable xperimental model to study the 
metabolic AEs associated with clozapine. 
OBJECT IVE:  The aim of this study was to assess the effects of clozapine adminis- 
tration for 28 days on body weight, glucose tolerance, blood glucose concentrations, 
plasma lipids, and insulin in C57BL/6 mice. 
METHODS:  C57BL/6 mice were grouped and treated with clozapine 2 or 10 mg/kg or 
vehicle intraperitoneally QD for 28 days. Body weight was assessed on days 0 (baseline), 
7, 14, 21, and 28, and glucose tolerance, blood glucose concentrations, insulin (calcu- 
lated by insulin resistance index [IRI}), and plasma lipids (including total cholesterol, 
TG, high-density lipoprotein cholesterol [ttDL-C], and low-density lipoprotein choles- 
terol) were assessed on day 29. 
RESULTS:  Sixty 10-week-old, male C57BL/6 mice were included in the study 
and were divided into 3 groups (20 mice per group). The body weight significantly 
decreased in the clozapine 10-rag treated group on days 14, 21, and 28 compared 
with the vehicle group (mean [SD] body weight: 21.61 [1.05] vs 22.79 [1.11], 
22.53 [1.05] vs 24.17 [1.24], and 22.21 [1.07] vs 24.99 [1.39] g, respectively; all, P < 
0.05). In the clozapine 10-mg/kg group, blood glucose concentrations significantly 
increased 0, 30, 60, arid 120 minutes after glucose administration compared with the 
vehicle group (mean [SD]: 6.67 [1.25], 25.34 [5.85], 12.68 [3.39], and 7.52 [1.45] mmol/L, 
respectively-, vs4.61 [0.78], 21.54 [6.55], 11.46 [3.46], and 6.55 [1.42] retool/L, respec- 
tively; all P < 0.05). The clozapine 10-mg/kg group also had significant increases in 
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plasma insulin concentrations compared with the vehicle group (12.70 [5.27] vs 
7.62 [4.54] plU/mL; P < 0.05) and IRI (3.01 [1.26] vs 1.51 [0.96]; P < 0.05). Plasma 
HDL-C concentration also significantly decreased in the clozapine 10-mg/kg group 
compared with the vehicle group (1.23 [0.25] vs 1.47 [0.16]; P < 0.05). 
CoNct.us lo I~I :  Clozapine 10 mg/kg was associated with significant decreases in 
body weight and significant increases in fasting blood glucose and glucose tolerance in 
these male C57BL/6 mice. (Curt Ther Res Clin Exp. 2008;69:142 149) ~) 2008 Excerpta 
Medica Inc. 
IKEY WORDS:  clozapine, body weight, blood glucose, insulin resistance, plasma lipid, 
mice. 
INTRODUCTION 
Clozapine is an atypical antipsychodc drug that is used in patients with treatment- 
resistant schizophrenia or schizoaffective disorder. It is effective in -30% to 60% of 
patients who are unresponsive to typical antipsychotics) However, clozapine has been 
associated with metabolic adverse vents (AEs) (eg, elevated body weight, blood glucose 
concentrations, cholesterol, triglycerides [TG]), all of which have deleterious effects on 
health and medication compliance. 2,3 It has been reported that more than one third of 
schizophrenic patients treated with clozapine for 5 years developed iabetes) 
Although studies 5 8 using experimental models have investigated changes in body 
weight associated with clozapine use, little focus has been directed toward study- 
ing the effects of clozapine on glucose tolerance, blood glucose concentrations, total 
cholesterol (TC), TG, and insulin in experimental models. Therefore, because of 
limited research, clozapine-induced metabolic abnormalities have not been clearly 
defined. Dwyer and Donohoe 5 found that unlike haloperidol, clozapine injection 
was associated with a dose-dependent i crease in blood glucose concentrations in
male C57BL/6 mice. Cheng et al 6 reported that male BALB/c mice treated with 
clozapine 10 mg/kg for 30 consecutive days had significant decreases in body weight 
and increased TC concentrations compared with those treated with cbzapine 2 mg/kg 
and vehicle. Arulmozhi et al 7 found that clozapine 10 mg/kg administered for 
7 days elevated blood glucose and TG concentrations in male Swiss albino mice but 
did not have a significant effect on insulin concentrations. A recent study by 
Tulipano et al 8 found that clozapine 7.5 mg/kg administered for 13 days was 
associated with hyperglycemia, and significantly higher plasma insulin concentra- 
tions in female rats. However, these studies 5,7,8 were limited by their short duration 
(3 hours 13 days) and the evaluation of few metabolic indexes in the experhnen- 
tal models. 6
The primary objective of this study was to determine the effects of clozapine admin- 
istration for 28 days on body weight, glucose tolerance, blood glucose concentrations, 
plasma lipids, and insulin. Because C57BL/6 mice have been found to be the species 
most sensitive to the hyperglycemic effect of chlorpromazine and particularly suscep- 
tible to developing diabetes after treatment with streptozotocin, 9,1° male C57BL/6 mice 
were the choice model. 
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MATERIALS  AND METHODS 
DRUGS 
Clozapine was provided by the Hunan Dongting Pharmaceutical Factory Co. Ltd., 
Hunan, China. The drug was dissoDed in 0.1M hydrochloric acid, neutralized to a pH 
~4 to 5 with 1M sodium hydroxide, and diluted with distilled water. The vehicle was 
comprised of the same solution (0.1M hydrochloric acid, neutralized to a pH of ~4~ 
with 1M sodium hydroxide, and diluted with distilled water) but without clozapine. 
EXPERIMENTAL  STUDIES  
The experimental facilities and protocol were reviewed and approved by the 
Institutional Animal Care and Use Committee of Second Xiangya Hospital of Central 
South University, Changsha, China. The 10-week-old male C57BL/6 mice were pro- 
vided by the Shanghai Slaccas Laboratory Animal Center, Shanghai, China. The mice 
were housed 10 per cage and maintained on a 12/12-hour light/dark cycle with food 
(standard laboratory chow diet) and water provided ad libitum. They were allowed to 
acclimatize to the environment for 7 days prior to the commencement of the study. 
Body weight and fasting blood glucose (FBG) were assessed at baseline. 
The mice were grouped and treated with either clozapine 2 or 10 mg/kg or the vd-ficle 
inrraperitoneally (IP) QD at 8:30 aM for 28 consecutive days. Body weight was recorded on 
days 0 (baseline), 7, 14, 21, and 28. To assess glucose tolerance, mice were ~asted overnight 
on day 29, and their blood glucose responses m IP administration f 25% glucose (2 g/kg) 
were determined. Blood glucose concentrations were assessed in the whole blood collected 
from the tail vein before glucose administration (ie, time 0, FBG) and 30, 60, and 120 min- 
utes after glucose administration. The mice were fasted for 6 hours after glucose administra- 
tion and were then anesthetized using sodium pentobarbital (Tianjin Jinyao Group Co., Ltd. 
Pharmaceuticals Group Co., Ltd., Tianjin, China) 130 mg/kg. The blood samples were im- 
mediatdy taken from the retro-orbital plexus and placed in ethylenediaminetetraacetic- 
coated tubes for plasma lipid and insulin determination. Plasma was separated by centrifu- 
gation (5000g for 5 minutes) and stored at ~0°C until analysis. 
BIOCHEMICAL  ANALYS IS  
Blood glucose was assessed using a portable glucometer (OneTouch ®Ultra ®, LifeScan 
Inc., Shanghai, China) and compatible blood glucose test strips. Plasma. insulin concentra- 
tions were determined using a commercially available radioimmunoassay kit for mouse 
insulin (lot number 20070401, Peking Furui Bioengineering Company, Peking, China). 
Concentrations of TC, TG, high-density lipoprotein cholesterol (HDL-C), and low-density 
lipoprotein cholesterol (LDL-C) were determined using a 7170A automatic analyzer 
(Hitachi, Tokyo, Japan). The insulin resistance index (IRI) for homeostasis model assess- 
ment was calculated using FBG and insulin concentrations zl by the following formula: 
IRI (FBG [mmol/L] × insulin [pIU/mL])/22.5. 
STAT IST ICAL  ANALYS IS  
All data are expressed as mean (SD). Between-group comparisons were analyzed 
using 1-way analysis of variance followed by post hoc analyses. A value ofP < 0.05 was 
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considered to be statistically significant. All statistical analyses were performed using 
SPSS version 10.0 (SPSS, Inc., Chicago, Illinois). A power analysis was not performed. 
RESULTS 
Sixty 10-week-old male C57BL/6 mice were included in the study and were divided into 
3 groups (20 in each group). During the experiment, 1 mouse in each group died. 
Table I illustrates baseline body weight and blood glucose concentration values in these 
C57BL/6 mice. 
There were no significant diffbrences in body weight and FBG between groups 
at baseline (mean [SD]: 22.55 [1.02], 22.95 [1.11], and 22.80 [1.05] g; 3.92 [0.42], 
3.98 [0.24], and 4.01 [0.24] mmol/L, clozapine 2, 10 mg/kg, and vehicle, respectively). 
The clozapine 10-mg/kg roup had a significant decrease in body weight at dws 14, 21, 
and 28 compared with the vehicle group (mean [SD]: 21.61 [1.05] vs 22.70 [1.11]; 
22.53 [1.05] vs 24.17 [1.24]; and 22.21 [1.07] vs 24.99 [1.39] g; respectively; all, P < 
0.05) (Figure 1). 
Figure 2 illustrates the changes in FBG concentrations in the 3 groups. The blood 
glucose concentrations significantly increased in the clozapine 10-mg/kg roup at 0, 30, 
60, and 120 minutes after glucose administration compared with the vehicle group 
(mean [SD] 6.67 [1.25] vs 4.61 [0.78] mmol/L; 25.34 [5.85] vs 21.54 ~6.55] mmol/L; 
12.68 [3.39] vs 11.46 [3.46] retool/L; and 7.52 [1.45] vs 6.55 [1.42] mmol/L, respectively; 
all, P < 0.05). 
Table II summarizes the changes in plasma concentrations of TC, TG, HDL-C, 
LDL-C, insulin, and IRI values in the 3 groups after 28 days of treatment. There were 
significant increases in plasma insulin concentrations in the clozapine 10-mg/kg roup 
compared with the vehicle group (12.70 [5.27] vs 7.62 [4.54] plU/mL; P < 0.05) and 
IRI (3.01 [1.26] vs 1.51 [0.96]; P < 0.05). However, there were no significant differ- 
ences in plasma insulin concentrations between the c]ozapine 2-mg/kg group and the 
vehicle group. Plasma HDL-C concentrations significantly decreased in the clozapine 
10-mg/kg roup compared with the vehicle (1.23 [0.25] vs 1.47 [0.16]; P < 0.05). 
DISCUSSION 
Cbzapine (2 and 10 mg/kg) administered IP fc)r 28 days significantly decreased the 
body weight in these male C57BL/6 mice, which was consistent with previous tudies "r',12 
reporting that clozapine treatment decreased body weight in aging male BALB/c mice 
and male \Vistar rats. 13 Because the decrease in body weight was believed to be associ- 
Table I. Baseline body weight and fasting blood glucose (FBG) in male C57BL/6  mice. 
Data are mean (SD). 
Groups Body Weight, g P FBG, mmol/L P 
Clozapine 2 mg/kg (n = 20) 22.55 (1.02) 3.92 (0.42) 
Clozapine 10 mg/kg (n = 20) 22.95 (1.11) 0.214 3.98 (0.24) 0.105 
Vehicle (n = 20) 22.80 (1.05) 4.01 (0.24) 
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Figure 1. Mean (SD) changes in body weight in male C57BL/6  mice treated with 
clozapine 2 mg/kg  (n = 19), clozapine 10 mg/kg  (n = 19), or vehicle (n = 19), 
administered intraperitoneal ly.  *P  < 0.05 versus vehicle-treated group. 
ated with hyperglycemia in male C57BL/6 mice treated with clozapine, it was suggested 
that some factors other than the body weight might have contributed to hyperglycemia. 
In the present study, plasma insulin concentrations and IRI significantly increased 
in the mice treated with clozapine 10 mg/kg but not with clozapine 2 mg/kg. Tulipano 
et al s reported that a single administration of clozapine 7.5 mg/kg in female rats 
significantly increased plasma insulin concentrations and IRI (both, P < 0.01). Since 
olanzapine and clozapine are atypical antipsychotic drugs and resemble ach other in 
chemical structure, the AEs of the 2 drugs might be expected to be similar. However, 
the results of this study were inconsistent with olanzapine studies 14,15 that found that 
female rats chronically treated with olanzapine developed hyperinsulinemia at lower 
doses (1 and 2 mg/kg) but not at higher doses (4 and 8 mg/kg). Our findings on insulin 
resistance associated with clozapine treatment in mice were consistent with the results 
of a clinical study by Henderson et al, 3 who reported clozapine- and olanzapine-treated 
patients displayed significant insulin resistance and impaired glucose ffectiveness 
the ability to stinmlate its own uptake and suppress its own release compared with 
risperidone-treated patients. Impaired peripheral glucose tolerance and increased glu- 
cose production from the liver might account for hyperglycemia with elevated plasma 
insulin concentrations. This cross-sectional study evaluated the insulin resistance and 
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Figure 2. Mean (SD) changes in blood glucose concentrations after 28 days of t reatment 
with clozapine 2 mg/kg  (n = 19), clozapine 10 mg/kg  (n = 10), or vehicle (n = 19) 
administered intraperitoneally to C57BL/6  mice in response to an IP glucose 
challenge. *P < 0 .05  versus vehicle-treated group. 
Table II. Mean (SD) changes in biochemical variables after 28 days of t reatment with 
clozapine (2 and 10 mg/kg)  administered intraperitoneally once daily versus 
vehicle in male C57BL/6  mice. 
TC, TG, HDL-C, LDL-C, Insulin, 
Group mmol/L  mmoi/L  mmoi/L  mmol/L piU/mL IRI 
Clozapine, 
2 mg/kg 
P 
Clozapine, 
10 mg/kg 
P 
Vehicle 
2.13 (0.17) 0.55 (0.24) 1.36 (0.08) 0.21 (0.04) 10.94 (5.97) 2.36 (2.00) 
0.205 0.546 0.198 0.214 0.125 0.258 
2.06 (0.46) 0.37 (0.16) -1.23 (0.25)* 0.26 (0.09) 12.70 (5.27)* 3.01 (1.26)* 
0.212 0.370 0.019 0.260 0.032 0.037 
2.31 (0.16) 0.44 (0.12) 1.47 (0.16) 0.27 (0.06) 7.62 (4.54) 1.51 (0.96) 
TC = total cholesterol, TG = triglyceddes; HDL-C = high-density lipoprotein cholesterol; LDL-C = low- 
density lipoprotein cholesterol; IRi = insulin resistance index, 
*P < 0,05 versus vehicle-treated group, 
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glucose ffectiveness in stable, schizophrenic patients treated with clozapine, olanzapine, 
or risperidone. The results of this study found a significant increase in insulin resistance 
(P 0.03) and impaired glucose ffectiveness (P 0.04) in clozapine- and olanzapine- 
treated patients compared with risperidone-treated patients. Clozapine was reported to 
inhibit glucose transporter p oteins in the plasma membrane of rat skeletal muscle cells 
and neuronal cells; however, the inhibitory effect was noncompetitively antagonized by 
glucose itself, l~ 
In the present study, the only significant change in plasma lipid concentrations 
was the decrease in HDL-C in the group treated with clozapine 10 mg/kg. This 
finding was inconsistent with the findings of previous experimental ~ and clinical 
studies. 17 In an experimental study, ~ mice treated with clozapine 10 mg/kg had 
higher TC concentrations compared with mice treated with clozapine 2 mg/kg and 
the vehicle. In a review of 590 patients treated with antipsychotics, xXfirshing et al iv 
found that the mean serum TC concentrations in clozapine-treated patients increas- 
ed by 5%, and 6 individuals in the clozapine group (n 40) required cholesterol- 
lowering drug treatment. A randomized, double-blind, 14-week trial 18 (n 157) 
found that clozapine, olanzapine, and haloperidol were associated with increased 
plasma glucose levels, and it also found that clozapine and olanzapine were associ- 
ated with increased cholesterol levels. The mean changes in glucose and cholesterol 
levels remained within clinical normal ranges but -14% of the patients developed 
abnormally high glucose levels during the course of their participation in the 
study. 
L IMITAT IONS 
The amount of food intake and the activity level were not assessed in this study, and 
we did not rule out the possibility that the results could have been affected by these 
2 factors. In addition, the sample size was small, and this might have also confounded 
the results of the study. 
CONCLUSION 
Clozapine 10 mg/kg was associated with a significant decrease in body wright and a sig- 
nificant increase in glucose tolerance and FBG in these male C57BL/6 mice. 
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